
Alkermes PLC
ALKSHealthcare|Drug Manufacturers - Specialty & Generic|Ireland
$51.95
-1.82 (-3.39%)
DCF (FCF)
$20.11
Earnings Power
$12.19
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
1811.28,
1879.29,
2072.58,
2334.36,
2636.26
],
"ebit_estimate": [
12.51,
208.62,
380.71,
672.25,
962.25
],
"ebitda_estimate": [
399.41,
390.68,
548.75,
802.72,
1023.09
],
"net_income_estimate": [
-65.62,
75.37,
297.05,
532.75,
779.36
],
"per_share_eps_estimate": [
-0.27,
0.52,
1.74,
3,
4.43
],
"eps_nri_estimate": [
-0.39,
0.39,
1.73,
3.05,
4.43
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
11.06,
12.53,
14.71,
15.92,
null
],
"pretax_income_estimate": [
-62.44,
115.55,
369.64,
633.08,
946.4
],
"operating_cash_flow_per_share_estimate": [
2.58,
1.95,
2.52,
2.57,
null
],
"roa_estimate": [
-2.2,
0.3,
2.1,
5.5,
null
],
"roe_estimate": [
-2.86,
8.4,
12.23,
9.5,
null
],
"gross_margin_estimate": [
81.69,
87.23,
87.29,
88.2,
88.13
],
"operating_cash_flow_estimate": [
428.79,
323.53,
417.98,
427.12,
null
],
"pettm_estimate": [
0,
100.68,
29.91,
17.34,
11.72
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "11.13",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 11.13,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": 10.21,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 10.52,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
457.82,
472.47,
488.11,
445.7,
461.08,
460.85,
468.05
],
"ebit_estimate": [
18.52,
22.87,
19.85,
-5.71,
12.51,
6.49,
11.43
],
"ebitda_estimate": [
106.64,
107.47,
102.35,
null,
null,
null,
null
],
"net_income_estimate": [
-3.37,
1.24,
2.85,
-25.28,
-7.36,
-12.3,
-6.82
],
"per_share_eps_estimate": [
0.01,
0.03,
0.04,
-0.15,
-0.05,
-0.08,
-0.04
],
"eps_nri_estimate": [
-0.02,
0,
0.02,
-0.15,
-0.05,
-0.08,
-0.04
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-3.21,
2.51,
-0.33,
-26.41,
-7.39,
-12.52,
-6.93
],
"operating_cash_flow_per_share_estimate": [
2.47,
2.48,
2.7,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
80.41,
80.7,
81.75,
84.7,
85.3,
85.3,
85.3
],
"operating_cash_flow_estimate": [
410.5,
412.17,
448.73,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "11.13",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 11.13,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": 10.21,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 10.52,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}